The role of PD-1/PD-L1 checkpoint in arsenic lung tumorigenesis

被引:7
|
作者
Xu, Wenhua [1 ,2 ]
Cui, Jiajun [1 ,3 ]
Wu, Linqing [1 ,4 ]
He, Caigu [1 ,5 ]
Chen, Gang [1 ]
机构
[1] Univ Kentucky, Dept Pharmacol & Nutr Sci, Coll Med, MN306,800 Rose St, Lexington, KY 40536 USA
[2] Univ Sci & Technol China, Dept Neurol, Affiliated Hosp 1, Hefei 230001, Anhui, Peoples R China
[3] Yichun Univ, Coll Med, Dept Biochem, Yichun 336000, Jiangxi, Peoples R China
[4] Fujian Med Univ, Sch Basic Med Sci, Dept Immunol, Fuzhou 350003, Fujian, Peoples R China
[5] Fujian Univ Tradit Chinese Med, Dept Histol & Embryol, Fuzhou 361000, Fujian, Peoples R China
关键词
Arsenic; Lung; Tumor; T cell; PD-1; PD-L1; REGULATORY T-CELLS; CANCER; CD8(+); EXHAUSTION; PROLIFERATION; IMMUNOTHERAPY; LYMPHOCYTES; EXPRESSION; MODELS; PD-L1;
D O I
10.1016/j.taap.2021.115633
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic exposure to environmental arsenic promotes lung cancer. Emerging evidence indicates that compromised host immunity, particularly T cell anti-tumor immunity, may play a critical role in cancer development. However, there is a knowledge gap in terms of the effects of arsenic exposure on T cell anti-tumor immunity and how that may contribute to arsenic lung carcinogenicity. Immunosuppression has been known as a risk factor for many types of cancer, including lung cancer. The development of cancer indicates the success of immunosuppression and escape of cancer cells from host anti-tumor immunity in which T cells are the major component. The anti-tumor immunity is mainly executed by CD8 cytotoxic T cells through their anti-tumor effector function, which can be regulated by immune checkpoint pathways. Some inhibitory receptors on the T cell membrane and their ligands form these pathways, among which programmed death-1 (PD-1), a T cell inhibitory receptor, and its ligand, programmed death-ligand 1 (PD-L1), are best characterized. A/J mice are naturally sensitive to pulmonary carcinogens, prone to develop spontaneous lung tumors later in life and have been frequently used as an animal model for lung tumorigenesis research. Chronic arsenic administration through drinking water has been shown to enhance tumor formation in the lungs of A/J mice. In the current study, using this mouse model we want to determine whether PD-1/PD-L1 plays a role in arsenic-enhanced lung tumorigenesis. The results showed that prolonged arsenic exposure up-regulated PD-1/PD-L1, increased regulatory T cells (Tregs), decreased CD8/ Treg ratio, inhibited T cell antitumor function in the lungs and enhanced lung tumor formation, while inhibition of PD-1/PD-L1 restored CD8/Treg ratio and T cell anti-tumor effector function, and mitigated arsenic-enhanced lung tumorigenesis. In addition, inhibition of PD-1/PD-L1 could be a potential preventive strategy to mitigate the tumorigenic action of chronic arsenic exposure.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
    Jorgensen, Jan Trost
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (02) : 131 - 133
  • [32] Immunohistochemistry of Immune Checkpoint Markers PD-1 and PD-L1 in Prostate Cancer
    Sharma, Meenal
    Yang, Qi
    Mcmahon, Loralee
    Miyamoto, Hiroshi
    MODERN PATHOLOGY, 2019, 32
  • [33] Neoadjuvant PD-1/PD-L1 Immune Checkpoint Inhibitors in Solid Tumors
    Zhao, S.
    Li, X.
    Wang, S.
    Wang, Y.
    Huang, D.
    Da, Y.
    Song, Z.
    Chen, J.
    Manegold, C.
    Peng, L.
    Xu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S651 - S651
  • [34] Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
    Xin Wang
    Gaochao Guo
    Hui Guan
    Yang Yu
    Jie Lu
    Jinming Yu
    Journal of Experimental & Clinical Cancer Research, 38
  • [35] Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint blockade therapy
    Zhang, Qi
    Yang, Chenying
    Gao, Xingsu
    Dong, Ju
    Zhong, Caiyun
    PHYTOTHERAPY RESEARCH, 2024, 38 (02) : 776 - 796
  • [36] PD-1–PD-L1 axis: efficient checkpoint blockade against cancer
    Alessia Errico
    Nature Reviews Clinical Oncology, 2015, 12 : 63 - 63
  • [37] Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
    Wang, Xin
    Guo, Gaochao
    Guan, Hui
    Yu, Yang
    Lu, Jie
    Yu, Jinming
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [38] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Iosune Baraibar
    Ignacio Melero
    Mariano Ponz-Sarvise
    Eduardo Castanon
    Drug Safety, 2019, 42 : 281 - 294
  • [39] Immunohistochemistry of Immune Checkpoint Markers PD-1 and PD-L1 in Prostate Cancer
    Sharma, Meenal
    Yang, Qi
    Mcmahon, Loralee
    Miyamoto, Hiroshi
    LABORATORY INVESTIGATION, 2019, 99
  • [40] PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
    Hartkopf, Andreas D.
    Taran, Florin-Andrei
    Wallwiener, Markus
    Walter, Christina B.
    Kraemer, Bernhard
    Grischke, Eva-Maria
    Brucker, Sara Y.
    BREAST CARE, 2016, 11 (06) : 385 - 390